The purpose of this study was to compare the efficacy of the new endothelial progenitor cell (EPC) capture stents with that of bare metal stents in coronary artery disease patients at high risk for instent restenosis and thrombosis. We randomly assigned 38 patients with lesions carrying a high risk of restenosis to have the Genous stent or a bare metal stent implanted. Lesions were considered high risk of restenosis if one of the following applied: a chronic coronary artery occlusion; a coronary artery stenosis with a length of more than 20 mm; a lesion in a coronary artery with a diameter of less than 2.8 mm by QCA; or any lesion in a diabetic patient or renal failure. At 6 month, the rate of the primary end point, composite of ISR & IST, was 26% in the Genous stent group when compared with 58% in the bare metal stent group [p=0.049]. It worth noting that no stent thrombosis was observed in the Genous stent group compared to 1 probable stent thromboses in the bare metal stent group (p=0.3). The cumulative rate of MACE (cardiac death, MI & clinically driven TLR) at 6 months was 26% in the Genous stent group (all due to clinically driven TLR) when compared with 52% in the bare metal stent group, a difference due to clinically driven target lesion revascularization (p-value = 0.1).